SEARCH · PubMed Health

Results for “Tenon Capsule”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

327 records · Page 19Linked to original sources

PubMed2004

Suprachoroidal haemorrhage complicating cataract surgery in the UK: a case control study of risk factors.

AIMS: To study the risk factors for suprachoroidal haemorrhage (SCH) complicating cataract surgery in the United Kingdom. METHODS: 109 cases of SCH complicating cataract surgery prospectively collected through the British Ophthalmological Surveillance Unit were compared with 449 controls that underwent cataract extraction from 13 "control centres" throughout UK in a case control study. 40 systemic, ophthalmic, and operative variables were examined. RESULTS: Statistically significant risk factors for SCH in univariate analysis included: older age (p<0.001), taking at least one cardiovascular medication (p<0.001), peripheral vascular disease (p = 0.014), hyperlipidaemia (p = 0.005), glaucoma (p<0.001), elevated preoperative intraocular pressure (p<0.001), sub-Tenon's local anaesthesia (LA) (p<0.001), topical LA (p<0.001), the lack of orbital compression following LA (p<0.001), posterior capsule (PC) rupture before SCH (p<0.001), elective extracapsular cataract extraction (ECCE) (p = 0.038), and phacoemulsification conversion (p<0.001). Logistic regression analysis identified the following significant independent risk factors: older age, taking at least one cardiovascular medication, glaucoma, elevated preoperative intraocular pressure, the lack of orbital compression, PC rupture before SCH, elective ECCE, and phacoemulsification conversion. CONCLUSION: The results allow identification of patients at risk of SCH. Attention to the various modifiable preoperative and intraoperative risk factors is recommended in order to minimise the risk of SCH.

Aged↗

PubMed1988

Clinico-histopathologic correlation of a successful glaucoma pump-shunt implant.

A 64-year-old diabetic man was treated for neovascular glaucoma with a pump-shunt implant (seton) after maximal medical therapy was unsuccessful. The seton, with supplemental agents, maintained the intraocular pressure (IOP) within a therapeutic range for 6 months, until the time of death from cardiac complications. Histopathologic evaluation of the eye showed the inlet of the seton in the periphery of the anterior chamber, not in contact with a coexisting anterior chamber intraocular lens (IOL). There was no fibrosis of the intracameral portion of the device. The tissue tract containing the silicon outlet tube extended from peripheral Descemet's membrane, through the sclera, to exit in the episcleral tissue over the posterior pars plana. Fibrous tissue originating from the episclera encased the external chambers of the seton. The internal contours of the fistulous tract, i.e., that portion adjacent to the seton, were smooth. There was no gross tissue hiatus at the exit port of the seton. The posterior wall of the fibrous capsule surrounding the seton in this region was diaphanous and immediately anterior to an area of cystic tissue comprising an equatorially placed bleb. The bleb was characterized by an irregular internal surface and a cystic cavity crossed by collagenous columns, suggesting it was the sub-Tenon's reservoir of aqueous. The success of the seton in this particular case may be due to a lack of fibrous reaction in the anterior chamber and the establishment of a stable filtering bleb in the equatorial region of the eye.

Anterior Chamber↗

PubMed1997

Stability of the antiproliferative effect of mitomycin-C after reconstitution.

PURPOSE: The purpose of this study was to determine the long-term stability of the antiproliferative effect of mitomycin-C (MMC) following reconstitution. METHODS: Identical MMC preparations were reconstituted from the crystalline form and then stored at room temperature or 4 degrees C. Cultured human Tenon's fibroblasts were exposed to MMC (0.5 mg/ml) for 2.5 min at 0, 3, 7, 10, 14, 21, 28, 35, and 42 days following reconstitution. After removal of the drug, fibroblast proliferation was measured by tritiated thymidine uptake. RESULTS: The percentage of inhibition was maintained at > 85% for both the room temperature and the 4 degrees C groups, and this inhibition persisted for the duration of the experiment. There was no statistically significant difference in the results between the storage temperatures. CONCLUSIONS: These data suggest that MMC retains its antiproliferative effect for at least 6 weeks following reconstitution and that this effect is not changed by storage temperature. Cost savings may be realized by storing MMC in unit-dose reconstituted aliquots for these longer periods, providing sterility can be assured.

Analysis of Variance↗